Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2018
At a glance
- Drugs Gallium 68 satoreotide (Primary) ; Lutetium-177-DOTA-satoreotide (Primary)
- Indications Carcinoid tumour; Gastric cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Renal cancer
- Focus Therapeutic Use
- 03 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 08 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.